November 14, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

87% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1025 216% 890 553 995
ERLYTX 54 61 113% 53 7 58
GI 100 108 108% 94 8 106
GU 256 314 122% 273 58 307
LEUK 354 763 215% 663 409 742
LUNG 817 554 68% 481 -263 553
LYMPH 181 373 205% 324 192 360
MELAN 364 0 0% 0 -364 0
MMYEL 192 107 56% 93 -85 101
MULT 25 45 179% 39 20 46
Total 2815 3350   2910 535 3268

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

November 14, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

87% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 212 37% 184 -366 200
PEOLC 52 28 53% 24 -24 46
PREV 169 0 0% 0 -169 0
SXQOL 958 609 63% 529 -349 593
Total 1757 849   737 -908 839

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

November 14, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

87% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 16 14 14
LEUK 21CTP.LEUK01 10 9 9
Total   26 23 23

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

November 14, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

87% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 707 200% 614 355 703
ERLYTX 42 50 117% 43 8 46
GI 157 138 88% 120 -19 134
GU 399 320 80% 278 -79 314
LEUK 182 347 190% 301 165 343
LUNG 551 370 67% 321 -181 369
LYMPH 173 287 165% 249 114 283
MELAN 228 9 4% 8 -219 10
MMYEL 135 66 48% 57 -69 63
MULT 14 20 143% 17 6 19
OTHER 57 61 107% 53 4 60
Total 2290 2375   2061 85 2344

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

November 14, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

87% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 167 31% 145 -367 162
GI 0 1 .% 1 1 1
PEOLC 37 25 68% 22 -12 39
PREV 341 216 63% 188 -125 223
SXQOL 665 496 74% 431 -169 479
Total 1577 905   787 -672 904

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

November 14, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 36 442 960 11.8 Jun-2030 6.6
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 39 1814 2400 70.2 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 2 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 9 15 86 1.7 May-2030 4.3
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 59 171 189 2.8 May-2027 5.4
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 4 0 296 0.2 > 15 Yrs > 15 Yrs
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 61 116 154 3.5 Sep-2027 5.9
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 30 135 224 6.7 Dec-2027 3.6
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 10 1 94 0.0    
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 39 7 44 0.2 > 15 Yrs > 15 Yrs
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 14 72 111 10.0 Feb-2027 1.4
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 97 1068 1273 8.0 Dec-2028 10.2
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 71 167 336 2.5 Jun-2032 11.6
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 26 77 500 3.8 Jan-2036 11.4
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 6 51 718 8.5 May-2033 7.1
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 19 34 102 3.7 May-2028 3.1
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 3 1 126 0.3 > 15 Yrs > 15 Yrs
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 29 98 335 4.5 Mar-2031 6.8
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 1 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 71 215 247 4.5 Jun-2027 6.5
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 5 3 102 0.6 Oct-2041 15.4
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 29 1407   52.5 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 43 29 44 0.7 Sep-2028 5.4
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 34 34 56 1.5 Jan-2028 4.1
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 3 2 117 0.6 > 15 Yrs > 15 Yrs
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 14 22 900 2.8 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 18 154 378 10.2 Sep-2028 3.4
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 20 15 306 1.0 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 93 4175   30.0 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 44 261 396 6.8 Jun-2028 5.3
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 40 44 173 0.8 Sep-2039 16.2
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 2 1 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 27 467 600 22.7 Apr-2027 2.7
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 64 47 92 3.2 Jan-2028 6.6
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 88 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 41 153 510 4.0 Apr-2034 10.9
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 35 56 142 2.3 Nov-2029 6.0
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 49 115 220 3.5 May-2029 6.6
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

November 14, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 99 478 498 3.3 May-2027 8.8
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 15 146 654 12.3 Apr-2030 4.7
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 5 19 1000 3.5 > 15 Yrs > 15 Yrs
PEOLC III S1501: Breast Stg IV, Card Tox Obs and w/ Carvedilol 09/15/2017 109 403 491 2.3 Dec-2029 12.2
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 43 712 777 16.8 Feb-2027 3.9
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 62 2701 3609 33.7 Jan-2029 7.4
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

November 14, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 8 14 50 1.8 Jun-2028 2.3
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 11 9 55 1.3 Sep-2029 3.8
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.